MediciNova, Inc. (MNOV)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About MediciNova, Inc.
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 135K | 123K | 152K | 187K |
| Gross Profit | 18K | 8K | 5K | 17K |
| Operating Income | -3.6M | -3.4M | -3.1M | -2.8M |
| Net Income | -3.3M | -3.1M | -2.8M | -2.6M |
| Diluted EPS | $-0.07 | $-0.06 | $nan | $-0.05 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 1.0M | 0.00 | 410K |
| Gross Profit | 0.00 | 31K | ||
| Operating Income | -14.6M | -9.9M | -12.7M | -13.3M |
| Net Income | -14.1M | -8.6M | -11.0M | -12.0M |
| Diluted EPS | $-0.29 | $-0.17 | $-0.23 | $-0.24 |